M2N to sell 52% stake in Chinese automotive parts company DKCA

The parent company of Sillajen will use the proceeds to finance future M&A deals

M2N to sell 52% stake in Chinese automotive parts company DKCA
Jae-Young Han 1
2022-12-28 11:22:02 jyhan@hankyung.com
Corporate restructuring

M2N( DK D&I Co. ), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its majority stake in its Chinese subsidiary DKC Autotomoitve (DKCA) to a Chinese electric vehicle (EV) parts maker based in Nanchang, Jiangxi Province.


DKCA, established in Jiangsu Province in 2003, is a manufacturer of diesel heaters for diesel filters, sensors, and solenoid valves for engine and powertrain applications.

M2N will dispose of 51.59% of its 70.59% stake in DKCA for about 5 billion won ($3.9 million) and retain the remaining 19%, becoming the second largest shareholder.

M2N's decision to sell its stake is to secure liquidity to finance expansion and build partnerships in the EV market in China.

Currently, it is reviewing several M&A deals to secure an additional growth engine and expects the deals will accelerate with the sale of its DKCA stake.

Seo Hong-min, CEO of M2N, has favored the M&A formula for expansion, including the acquisition of lender The Leadcorp, Inc. in 2008 and SillaJen last year.

Write to Jae-Young Han at jyhan@hankyung.com

S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug

S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug

Kim Jae-kyung, CEO of Korean biotech company SillaJen South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swiss pharmaceutical company.SillaJen plans to expedite clinical development and promote technolo

SillaJen shares jump as exchange maintains listing, allows resumed trade

SillaJen shares jump as exchange maintains listing, allows resumed trade

SillaJen researchers work on anti-cancer virus drugs (File photo, courtesy of SillaJen) Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the stock’s listing, given its measures to diversify its

Scandal-hit SillaJen faces higher delisting risk

Scandal-hit SillaJen faces higher delisting risk

Retail investors held picketing to protest against Korea Exchange's tentative decision to delist SillaJen on Jan. 18 South Korea's SillaJen Inc., once the largest stock on Kosdaq by market value, faces a higher risk of being kicked out of the country's junior stock market, dealing a heavy blow

(* comment hide *}